Eiger Cleared To Liquidate, Repay Creditors Under Ch. 11 Plan
Drug developer Eiger Biopharmaceuticals will wind down its business and distribute proceeds from sales of its rare-disease treatments to creditors and shareholders under a Chapter 11 plan approved by a Texas...To view the full article, register now.
Already a subscriber? Click here to view full article